EUVIMEDEUVIMED entdecken
Open Access

The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1

Carmen J Reynolds iD, Zejfa Haskic iD, Barbara M Seide iD, Michael F Romero iD, David S Goldfarb iD, John C Lieske iD, Lada Beara-Lasic iD

Clinical Journal of the American Society of Nephrology · 2026-05 · 21 (5) · 811-821

DOI: 10.2215/cjn.0000000978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 27.02.2026. Verfasst von Carmen J Reynolds und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Mayo Clinic Women's Health Research Center, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Fibroblast growth factor 23 and 24,25-dihydroxyvitamin D are positively correlated and are significantly lower in Dent disease than in idiopathic calcium kidney stones patients. Dent patients with low 24,25-dihydroxyvitamin D had greater hypercalciuria and proteinuria, and, among adults, higher 1,25-dihydroxyvitamin D concentrations. Moderate phosphate supplementation mitigates hypercalciuria.

Background

Hypercalciuria is a prominent characteristic in Dent disease type 1 (DD1) and is associated with kidney stones and nephrocalcinosis. The objectives of this study were to assess fibroblast growth factor 23 (FGF23) and 24,25-dihydroxyvitamin D (24,25(OH) 2 D) in DD1 patients and investigate the effects of phosphate supplementation on urinary calcium excretion.

Methods

Serum and 24-hour urine assessments from adult and pediatric DD1 patients ( N =10 adults; N =9 pediatrics) were compared with adult control subjects with a history of idiopathic calcium kidney stones and hypercalciuria ( N =9). Adult DD1 patients and control participants completed an oral phosphate supplementation intervention (1 g/d×14 days) with reassessment immediately after intervention.

Results

FGF23 was significantly lower in DD1 than in the control cohort (adults, P = 0.006) and positively correlated with 24,25(OH) 2 D across all study cohorts. The concentrations of 24,25(OH) 2 D were low with conversion ratios (25-hydroxyvitamin D: 24,25(OH) 2 D) exceeding the clinical reference limit for five of 10 adults and six of 9 pediatric DD1 patients. The DD1 cohorts were then stratified by the 24,25(OH) 2 D ratio into “normal” and “low” 24,25(OH) 2 D. Adult DD1 patients with low 24,25(OH) 2 D ( n =5) had lower FGF23, higher 1,25-dihydroxyvitamin D, greater urine calcium, and greater urine protein. Pediatric stratified data mirrored that in adults with the exception of no difference in serum 1,25-dihydroxyvitamin D. Phosphate supplementation was effective in decreasing urine calcium in both adult DD1 and control adult cohorts.

Conclusions

Clinical measurement of 24,25(OH) 2 D is a novel and useful analysis for evaluating the severity of calcium and protein dysregulation in DD1. In addition, moderate phosphate supplementation effectively mitigates urine calcium excretion in DD1 adult patients. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT02016235.

Schlagwörter

Stichwörter der Autor:innen

bones, stones, and mineral metabolismdent diseasegenetic kidney diseasehypercalciuriavitamin D

Autor:innen und Institutionen

  • Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
  • Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
  • New York Harbor VA Healthcare System, New York, New York.
  • NYU Langone Health, New York University Grossman School of Medicine, New York, New York.

ORCID-Profile: Carmen J Reynolds, Zejfa Haskic, Barbara M Seide, Michael F Romero, David S Goldfarb, John C Lieske, Lada Beara-Lasic

Förderung

  • NIDDK NIH HHS
  • Mayo Clinic Women's Health Research Center
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Reynolds, C. J., Haskic, Z., Seide, B. M., Romero, M. F., Goldfarb, D. S., Lieske, J. C., & Beara-Lasic, L. (2026). The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1. Clinical Journal of the American Society of Nephrology, 21(5), 811-821. https://doi.org/10.2215/cjn.0000000978

Vancouver

Reynolds CJ, Haskic Z, Seide BM, Romero MF, Goldfarb DS, Lieske JC, et al. The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1. Clinical Journal of the American Society of Nephrology. 2026;21(5):811-821. doi:10.2215/cjn.0000000978

BibTeX
@article{Reynolds2026,
  author = {Reynolds, Carmen J and Haskic, Zejfa and Seide, Barbara M and Romero, Michael F and Goldfarb, David S and Lieske, John C and Beara-Lasic, Lada},
  title = {The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {5},
  pages = {811--821},
  doi = {10.2215/cjn.0000000978}
}
Kostenlos starten →